The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs

Basit Öğe Kaydı
dc.contributor.authorBakbak B.
dc.contributor.authorOzturk B.
dc.contributor.authorGonul S.
dc.contributor.authorGedik S.
dc.date.accessioned2020-03-26T19:32:06Z
dc.date.available2020-03-26T19:32:06Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To compare the effects of bevacizumab and ranibizumab on the visual function and macular thickness in the contralateral (untreated) eye of patients with bilateral diabetic macular edema (DME). Materials and Methods: Thirty-nine patients with bilateral DME, who had been treated with both bevacizumab and ranibizumab in the same eye, were considered retrospectively for this study. Recorded outcome measurements included the best-corrected visual acuity (BCVA) assessment with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the central subfield macular thickness (CSMT) measurement of the contralateral, uninjected eye before and at 4 weeks after the injections. Results: The median BCVA of the uninjected eye was 50 ETDRS letters and the median CSMT was 459 ?m preceding the bevacizumab injection whereas at the control appointment, 4 weeks after the injection, the median BCVA had increased to 52 letters (P = 0.098), and the median CSMT had decreased to 390 ?m (P = 0.036). The mean interval between the bevacizumab and ranibizumab treatments was 4.79 1.52 months. The measurements of the untreated eye after the ranibizumab treatment showed that the median BCVA decreased from 55 to 52 letters, and the median CSMT increased from 361 ?m to 418 ?m (P = 0.148 and P = 0.109, respectively). Conclusions: In contrast to ranibizumab, the intravitreal administration of bevacizumab resulted in a statistically significant decrease in macular thickness in the untreated eye in patients with bilateral DME. © 2016 Oman Ophthalmic Society | Published by Wolters Kluwer Medknow.en_US
dc.identifier.doi10.4103/0974-620X.176100en_US
dc.identifier.endpage48en_US
dc.identifier.issn0974620Xen_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage44en_US
dc.identifier.urihttps://dx.doi.org/10.4103/0974-620X.176100
dc.identifier.urihttps://hdl.handle.net/20.500.12395/34323
dc.identifier.volume9en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMedknow Publicationsen_US
dc.relation.ispartofOman Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAntivascular endothelial growth factor treatmenten_US
dc.subjectbevacizumaben_US
dc.subjectdiabetic retinopathyen_US
dc.subjectmacular edemaen_US
dc.subjectranibizumaben_US
dc.titleThe effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu